Diagnosis and treatment of post-transfusion iron overload in pediatric hematology: literature review ; Диагностика и лечение посттрансфузионной перегрузки железом в детской гематологии: обзор литературы

Συγγραφείς: N. A. Batmanova, T. T. Valiev, K. I. Kirgizov, S. R. Varfolomeeva, Н. А. Батманова, Т. Т. Валиев, К. И. Киргизов, С. Р. Варфоломеева

Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 3 (2020); 70-77 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 3 (2020); 70-77 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-3

Θεματικοί όροι: наследственные гемохроматозы, chelation therapy, deferasirox, myelodysplastic syndrome, hereditary hemochromatosis, хелаторная терапия, деферазирокс, миелодиспластический синдром

Περιγραφή αρχείου: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/627/573; Slonim A.D., Joseph J., Turenne W., Sharangpani A., Luban N.L.C. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008:48(1):73–80. doi:10.1111/j.1537-2995.2007.01484.; Bercovitz S., Josephson C. Transfusion considerations in pediatric hematology and oncology. Hematol Oncol Clin North America 2019;33(5):903–13. doi:10.1016/j.hoc.2019.05.011.; Gauvin F., Champagne M., Robillard P. Long-term survival rate of pediatric patients after blood transfusions. Transfusion 2008;48(5):801–8. doi:10.1111/j.1537-2995.2007.01614.; Jang J.H., Lee J.-H., Yoon S.-S., Jo D.-Y., Kim H.-J., Chung J., Lee J.W. Korean guidline for iron chelator therapy in transfusion-indused iron overload. J Korean Med Sci 2013;28:1563–72. doi:10.3346/jkms2013.28.11.1563.; Wrighting D., Andrews N. Iron homeostasis and erythropoiesis. Curr Top Dev Biol 2008;82:141–67. doi:10.1016/S0070-2153(07)00006-3.; Brissot E., Bernard D., Loreal O., Brissot P., Troadec M.-B. Too much iron: a mask foe for leukemias. Blood Rev 2020;39:100617. doi:10.1016/j.blre.2019.100617.; Som D., Jodie B.L. Overview of iron metabolism in health and disease. Hemodial Int 2017;21(Suppl 1):6–20. doi:10.1111/hdi.12542.; Савченко В.Г., Абдулкадыров К.М., Масчан А.А., Сметанина Н.С., Голенков А.К., Кохно А.В., Сысоева Е.П., Савинова М.Т., Шелехова Т.В., Финогенова Н.А., Зубаровская Л.С., Капланов К.Д., Кравченко Е.Г., Лопатина Е.Г. Открытое многоцентровое исследование деферазирокса в лечении посттрансфузионной перегрузки железом у больных миелодиспластическими синдромами, талассемией и другими формами анемий. Гематология и трансфузиология 2015;60(4):7–14.; List A.F. Iron overload in myelodysplastic syndromes. Diagnosis and management. Cancer control 2010;17 Suppl:2–8. doi:10.1177/107327481001701s01.; Siddique A., Kowdley K.V. Review article: the iron overload syndromes. Aliment Pharmacol Ther 2012;35(8):876–93. doi:10.1111/j.1365-2036.2012.05051.; Циммерман Я.С. Первичный (наследственный) гемохроматоз. Клиническая медицина 2017;95(6);513–8. doi: 0.18821/0023-21492017-95-6-513-518.; Emy P.Y., Levin T.L., Sheth S.S., Ruzal-Shapiro C., Garvin J., Berdon W.E. Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. Am J Roentgenol 1997;168:1011–5. doi:10.2214/ajr.168.4.9124106.; Shan J., Kurtin E.S., Arnold L., Lindroos-Kolqvist P., Tinsley S. Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clin J Oncol Nursing 2012;16 Suppl:37–46. doi:10.1188/12.CJON.S1.37-46.; Gattermann N. Overview in guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24–9. doi:10.1007/s12185-008-0118-z.; Kushner J.P., Porter J.P., Olivieri N.F. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47–61. doi:10.1182/asheducation-2001.1.47.; Coates T., Wood J. How we manage iron overload in sickle cell patients. Br J Haematol 2017;177(5):703–16. doi:10.1111/bjh.14575.; Brissot P., Troadec M.-B., Loreal O., Brissot E. Pathophysiology and classification of iron overload diseases. Transfus Clin Biol 2019;26(1):80–8. doi:10.1016/j.tracli.2018.08.006.; Trinder D., Fox C., Vautier G., Olynyk J.K. Molecular pathogenesis of iron overload. GUT 2002;51(2):290–5. doi:10.1136/gut.51.2.290.; Delea E.T., Edelsberg J., Sofrygin O., Thomas S.K., Baladi J.F., Phatak P.D., Coates T.D. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-depending thalassemia: a literature review. Transfusion 2007;47(10):1919–29. doi:10.1111/j.1537-2995.2007.01416.x.; Baran E.J. Chelation therapies: a chemical and biochemical perspective. Curr Med Chem 2010;17(31):3658–72. doi:10.2174/092986710793213760.; Goldberg K.E., Neogi S., Lal A., Higa A., Fung E. Nutritional deficiencies are common in patients with transfusion-dependent thalassemia and associated with iron overload. J Food Nutr Research 2018;6(10):674–81. doi:10.12691/jfnr-6-10-9.; Bollig C., Schell L.K., Rucker G., Allert R., Motschall E., Niemeyer C.M., Bassler D., Meerpohl J.J. Deferazirox for managing irin overload in people with thalassemia. Cochrane Database Syst Rev 2017;2017(8):CD007476. doi:10.1002/14651858.CD007476.pub3.; Messa E., Ciloni D., Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv Hematol 2010;2010:756289. doi:10.1155/2010/756289.; Kontoghiorghe C.N., Kontoghiorghes G.J. Efficacy and safety of ironchelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Therapy 2016;10:465–81. doi:10.2147/DDDT.S79458.; Leitch A.H., Gatterman N. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Crit Rev Oncol Hematol 2019;141:54–72. doi:10.1016/j.critrevonc.2019.06.002.; https://journal.nodgo.org/jour/article/view/627

Διαθεσιμότητα: https://journal.nodgo.org/jour/article/view/627
https://doi.org/10.21682/2311-1267-2020-7-3-70-77